Qarziba 20,25 mg/4,5 ml, Konzentrat zur Herstellung einer Infusionslösung

7680674630012 CH-67463 Konzentrat
Qarziba 20,25 mg/4,5 ml, Konzentrat zur Herstellung einer Infusionslösung
Qarziba 20,25 mg/4,5 ml, Konzentrat zur Herstellung einer Infusionslösung
Qarziba 20,25 mg/4,5 ml, Konzentrat zur Herstellung einer Infusionslösung
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Flasche(n)
Galenic form
Konzentrat
Galenic group
Tinkturen/Desinfektion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
26/08/2024
Summary of Product Characteristics
Français
26/08/2024
Summary of Product Characteristics
Italien
26/08/2024

Detailed composition

Substance Quantity Type Category
(N/A)
20.25 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK

Authorization holder

Medius AG

4132 Muttenz

Authorization information

Swissmedic authorization number
67463
Drug name
Qarziba, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOINF
ATC Code
L01FX06
Authorization status
Z
Dispensing category
A
First authorization
18/04/2024
Authorization expiration date
17/04/2029
IT Number
07.16.1.
Domain
Human medicine
Field of application
Neuroblastoma

Package details

Description (FR)
QARZIBA conc perf 20.25 mg/4.5ml flac 4.5 ml
Description (DE)
QARZIBA Inf Konz 20.25 mg/4.5ml Durchstf 4.5 ml
Market launch
18/04/2024
Narcotic (BTM)
No